Background: Because of the growing prevalence of terminal heart failure on the one hand and organ shortage on the other hand, an optimal care of heart transplant recipients based on the knowledge of potential risk factors not only early, but also in a long-term course after heart transplantation is of great importance. Therefore, the aim of the present study was to identify predisposing factors for late mortality in this patient collective.
INTRODUCTION
Heart failure is an increasing health disorder worldwide [1] . As ultima ratio therapy, heart transplantation (HTx) has been proven to be an effective method of treatment in selected groups of patients with terminal heart failure refractory to other treatments [2] . However, a declining number of heart donors is a growing problem [3] which demands optimized management of the pre-, peri-and post transplantation stages in order to effectively prolong organ function and reduce mortality. In contrast to numerous investigations on risk factors, potential complications and therapy options in the early phase following HTx [4, 5] , there are relevantly few studies examining factors influencing survival many years after HTx [6] [7] [8] .
Furthermore, the results of these studies cannot be extrapolated to long-term survival as various factors and/or to a different extent may be associated with short-and long-term survival [6, 7, 9, 10] . Some determinants such as malignancy, infection [6, 7, 11] , chronic rejection [7, 11] , chronic allograft vasculopathy [11] , idiopathic dilated cardiomyopathy and younger recipient age [8] were associated with late mortality following HTx. However, factors predicting mortality in long-term heart transplant survivors are still unknown in many cases.
Therefore, the aim of the present study was to define determinants favoring prolonged survival in heart transplant patients. Beyond clinical, standard laboratory and apparative findings, the focus was placed on results from immune monitoring which reflects present immune/inflammatory status of patients.
METHODS

Data collection
The current retrospectively analyzed data were collected during the last control visits of heart transplant patients in the out-patient Department of Cardiology I at the University of Muenster. Of 483 patients who underwent HTx in the Department of Cardiothoracic Surgery at the University of Muenster between 1990 and 2018, 311 were excluded from the present study because of loss to follow-up (n = 309) or HTx less than 3 years till follow-up (n = 2) ( Fig. 1 ). During follow-up visits routine examinations including patient history, current complaints and medication, physical examination, assessment of functional capacity, arterial pressure, electrocardiogram, echocardiography and laboratory blood tests were conducted.
Standard laboratory blood tests consisted of measurements of electrolyte concentrations, renal and hepatic function, blood count, clotting parameters, inflammatory factors, NT-pro-B-type natriuretic peptide (NT-proBNP) and levels of immunosuppressive drugs such as cyclosporine A (CsA), everolimus, tacrolimus, mycophenolate mofetil (MMF) and prednisolone depending on the current immunosuppressive medication. Additionally, immune monitoring encompassing total lymphocyte number, numbers and percentages of CD4+, CD8+, CD19+ and natural killer cells was performed. Further, in order to exclude current relevant viral or fungal infections respective molecular and serological examinations were conducted.
Inclusion criteria were HTx at least 3 years till follow-up and age > 18 years at followup. Additionally, only patients in whom all the above mentioned parameters were determined within one visit at latest one year before the current assessment of the alive status or the date of death were enrolled in the study. All instable patients defined as patients presenting a status demanding relevant changes in their current medication and/or hospitalization were excluded from the study. Heart retransplantation was an additional exclusion criterion.
The study was performed according to the Declaration of Helsinki and the study protocol was approved by the local Ethics Committee of the University of Muenster.
Statistical analysis
Statistical analysis was conducted with IBM SPSS Statistics, version 25. Parametric values were expressed as means  standard deviation (SD). Differences between the means of the two groups were assessed by the Student t-test. Comparisons between categorical variables were performed using the χ 2 test. Two-tailed bivariate correlations were determined by the Pearson coefficient.
Potential risk factors for death were examined by the use of univariable and multivariable Cox proportional hazard function analyses. Variables showing a p < 0.05 in the univariate Cox analysis were introduced in a multivariable Cox model and a stepwise selection process was used to select the final independent predictors of mortality. Survival in groups depending on the risk factors identified in the multivariable Cox analysis was compared with the log-rank test and was illustrated using the Kaplan-Meier curves. P < 0.05 was defined as statistically significant.
RESULTS
Patient characteristics
172 patients at least 3 years after HTx (mean: 13.2  6.4 years) were divided into two groups according to survival (survivors, n = 133; non-survivors, n = 39). There were no significant differences in demographics, including age, sex and body mass index (BMI), the Table 2 .
Immunosuppression and rejection
The most frequent immunosuppressive therapy in both patient groups was a CsAbased one, followed by everolimus and tacrolimus therapies ( Fig. 2A ). The overwhelming number of survivors and non-survivors were on an additional therapy with low-dose prednisolone (n = 104, 78.2% vs. n = 34, 87.2%, p = 0.215) without differences in daily doses 2.2  1.6 ng/mL, p = 0.962, respectively).
Cellular-mediated rejections were classified into three grades according to the International Society of Heart and Lung Transplantation (ISHLT) grading system [12] .
Total rejection number from HTx till the last follow-up was similar in both groups.
There was a tendency in the frequency of therapy requiring rejections toward the non-survivor group. Of note, the vast majority of therapy requiring rejections occurred within two years after HTx in both groups (Table 3) .
Immunological status and inflammation
Immunological monitoring revealed significantly lower percentage of CD4+ cells among all lymphocytes in the blood in non-survivors versus survivors. Conversely, CD8+ cell portion was relevantly higher in this patient group. As a consequence, the CD4/CD8 ratio tended to be lower in non-survivors. In contrast, there were no significant differences in the levels of other lymphocyte populations, such as CD19+ cells and natural killer cells between the groups.
Inflammatory response expressed as elevated leukocyte numbers, C-reactive protein (CRP) and interleukin (IL)-6 levels was significantly more pronounced in non-survivors (Table 3) .
Chronic kidney disease, heart failure and anemia
Non-survivors were characterized by worse renal function expressed as a lower glomerular filtration rate (GFR) and higher urea concentrations in the blood. Moreover, the diagnosis of anemia, defined according to the World Health Organization classification as haemoglobin (Hb) < 13 g/dL for men and Hb < 12 g/dL for women [13] , was significantly more frequent in non-survivors. The morphological and biochemical analysis of erythrocytes showed macrocytic and hypochromic anemia.
NT-pro-B-type natriuretic peptide (NT-proBNP) values were significantly higher in non-survivors, although echocardiographically estimated LVEF did not differ between the groups ( Table 4 ).
Univariate and multivariate Cox analyses
In the multivariate Cox analysis only five determinants among other potential risk factors tested in the univariate Cox analysis such as NYHA stages II and III vs. I (p = 0.033) and dialysis (p = 0.108) showed a clear, statistically significant negative influence on the survival of heart transplant patients. These were: percentage of CD4+ cells < 42% (hazard ratio [HR]: 1.984, confidence interval [CI]: 1.020-3.859, p = 0.044), CRP  0.5 mg/dL (HR:
3.422, CI: 1.767-6.626, p < 0.001), rejections requiring therapies (HR: 2.236, CI: 1.157-4.319, p = 0.017), early onset of transplant vasculopathy < 5 years following HTx (HR: 2.741, CI: 1.145-6.558, p = 0.024) and no use of BB (HR: 2.358, CI: 1.194-4.656, p = 0.013; Fig. 3 ).
Correlations
The above mentioned five factors influencing survival in the multivariate analysis were correlated with other measures. Significant correlations are depicted in Table 5 .
DISCUSSION
The present study has shown that the main factors influencing survival in long-term follow-up after HTx were connected to immunomodulation/inflammation, severe organ rejections, early onset of transplant vasculopathy and drug therapy.
Specifically, higher percentages of CD4+ cells were associated with significantly longer survival. CD4+ cells are central cells in the rejection process [14] . In the early stage after HTx these cells may mediate rejection responses against donor tissue causing cardiovascular damage with subsequent organ failure. Therefore, the consequent immunosuppressive therapy is mandatory to preserve normal structure and function of the transplanted heart. In contrast, aggressive immunosuppression in a long-term course is not needed because of a slowly developing immune tolerance. The present findings indicate that lower percentages of CD4+ cells may be associated with enhanced mortality many years after HTx. It may be related to two main reasons. On the one hand, reduced CD4 levels result mostly from higher blood concentrations of immunosuppressive drugs [15] . In the current study, subgroup analysis according to the immunosuppressive medication demonstrated that non-survivors treated with CsA-based immunosuppressive therapy had relevantly higher CsA blood concentrations compared to the corresponding survivor subgroup. As CsA therapy is connected to many side-effects, e.g. renal insufficiency [16] which indeed was more pronounced in the non-survivor group, relatively low CD4+ cell percentages could be seen as an indicator of an overly intensive drug therapy. However, in the subgroup of patients with tacrolimus-based immunosuppressive treatment, there were no significant differences in tacrolimus blood concentrations in spite of significantly higher CD4+ cell levels in survivors.
In the subgroup with everolimus as a main immunosuppressant there were no relevant differences in everolimus or CD4 concentrations between survivors and non-survivors. No significant correlations were found between the percentage of CD4+ cells and the levels of the immunosuppressive medication used. Moreover, although, it is known that low blood levels of CD4+ cells may lead to the renal failure [17] and vice versa reduced CD4+ cell percentage may be the result of an impaired renal function [18] , no relevant correlations were demonstrated for CD4% and renal function. This emphasizes the high complexity of an immune answer indicating individual response of organism to immunosuppressive therapy, renal function and/or additional mechanisms influencing CD4+ cell levels in the blood. This result shows that monitoring of drug concentrations and/or of renal function in the blood may be not sufficient to assess current immunological status and thus its impact on the body [19] .
The other explanation of low CD4+ cell-associated mortality in the current collective of patients could be the creation of a prolonged subclinical immunosuppressive state with susceptibility to developing sustained inflammation, infections and tumour diseases. Indeed, increased leukocyte numbers were found to be significant, as well as CRP and IL-6 levels in non-survivors. Additionally, CRP correlated negatively with CD4+ cell percentages.
Furthermore, CRP was another factor that predicted higher mortality in a multivariate analysis. Chronic inflammation, indicated by increased CRP levels is a known independent factor for cardiovascular and all-cause mortality [20] . Prolonged immunosuppressive state may have also influenced a tendency toward increased prevalence of precarcinoma/tumor diseases [21] .
This could have also emerged from the side-effects of immunosuppressive drugs [21] . In the present study patients were free of infections based on anamnesis, physical examination, laboratory and microbiological tests at follow-up. However, occult infections, not routinely tested in the current laboratory, could not be excluded. The results from the mortality data support the above hypothesis as the main causes of death in our patient population were malignant tumors and infections.
Furthermore, it has been shown that CD4 cell lymphopenia may accelerate the development of cardiovascular atherosclerotic complications in renal transplant recipients [22] which augments mortality risk. In the current study there were no significant differences in the occurrence and severity of transplant vasculopathy between survivors and nonsurvivors despite relevantly different levels of CD4+ cells. However, data concerning CD4+ cell blood concentrations in the past as atherosclerotic lesions were detected and invasively treated are missing, so that this issue cannot be covered by the present study.
The next parameter which was shown to be relevant in the context of survival was the presence of rejections requiring therapies in the past. In contrast, weaker rejections without the need for drug therapy were not of relevance regarding mortality. As gross of rejections requiring therapies occurred early after HTx, points to a dual role of CD4+ cells in the outcome depending on the time course after HTx. Whereas an intense suppression of immunological response involving activation of CD4+ cells prevents rejections and thus organ failure early after HTx, the continuation of a strong elimination of CD4+ cells years following HTx may contribute to higher mortality. Therefore, continuous adjustments of immunosuppressive therapy strategies as well as close monitoring of immunological status in the blood are important actions at every time stage after HTx.
Immunological status, together with the side-effects of drug therapy, cardiovascular risk factors and donor and recipient demographics at the time point of HTx procedure influence the onset of transplant vasculopathy [23] . Interestingly, the present study showed that there were no significant differences in the prevalence of transplant vasculopathy between survivors and non-survivors at the time point of the last follow-up. The presence of transplants vasculopathy was also not a factor influencing mortality in the Cox analysis.
Patients with transplant vasculopathy were characterized by elevated cardiovascular risk factors such as diabetes mellitus, renal insufficiency, they were more obese, had longer heart transplant from older and more obese donors and differed from non-transplant vasculopathy patients in cardiovascular medication. Since survivors presented significantly less frequent transplant vasculopathy less than five years after HTx compared with non-survivors in this study, this finding suggests that, not just the presence of transplant vasculopathy is critical for survival, but much more the time point of its development. It is known that the immune mechanisms and the influence of immunomodulating drug therapy prevail in the development of transplant vasculopathy at early stages, whereas classical cardiovascular risk factors may play a greater role later in the time course [23] . In the present patient population typical cardiovascular risk factors at follow-up were equally distributed across both groups. Patients with early onset of transplant vasculopathy were significantly older at the HTx and the hearts were derived from tendentially more obese donors. This suggests that the early occurrence of transplant vasculopathy and thus higher risk of longer duration of transplant vasculopathy and the pathomechanisms determining its onset, including donor-and recipient-associated factors may influence long-term outcome following HTx.
The last factor presented to influence survival of long-term heart transplant patients was the therapy with BB in this study. Survivors obtained significantly more frequent BB treatment than non-survivors. As a consequence, the average heart frequency tended to be lower in these patients. Beta-blocker is a known drug reducing mortality in patients with systolic heart failure and in selected populations of patients with myocardial infarction without systolic heart failure [1, 24] . Its beneficial effects on cardiovascular system encompass blockade of beta-adrenoreceptor, reduction in sympathetic activity, antioxidant and anti-arrhythmic properties, positive actions on myocardial metabolism and protection of endothelium [25] . Patients did not show systolic heart failure with on average preserved LVEF in both groups. Some patients were on diltiazem instead of BB therapy. In contrast to BB which application has been associated with better long-term outcomes after HTx, the use of diltiazem did not show any advantage with regard to survival despite a similar reduction of heart frequencies as under BB [26] . Although it is known that diltiazem enhances CsA and tacrolimus concentrations in the blood and thus reduces the need of higher CsA and tacrolimus doses [27] and has positive effects on transplant vasculopathy [23] and cardiopulmonary performance [28] , giving preference to BB therapy in a selected group of patients could be advantageous considering results from this study.
Limitations of the study
The present study has some limitations. The most important one is connected to its retrospective character and thus descriptive results. Additionally, the number of patients enrolled was relatively low. On the other hand, this statement relativizes itself when taking into consideration the monocentric design of the study. Furthermore, no differentiation into CD4 subtypes such as regulatory and effector T cells [29] was performed. However, the aim of this work was to search for simple predictors of mortality which can be determined easily and inexpensively in routine diagnostics. Finally, the findings from immune monitoring were completely available only at the last follow-up visit, so we cannot answer the question about the blood levels of immune cells as transplant vasculopathy was initially diagnosed or as respective organ rejections were detected and treated.
CONCLUSIONS
Taken together, the present study showed that lower CD4+ blood levels, systemic inflammation, organ rejections requiring therapies, early diagnosis of transplant vasculopathy and no use of BB therapy were associated with increased mortality in a long-term time course after HTx. Data are presented as a mean ± standard deviation or number (percentage); *p < 0.05 (significant); ACEangiotensin-converting-enzyme; AT1Rangiotensin II type 1 receptor; BPblood pressure; CADcerebral artery disease; HTxheart transplantation; LVEFleft ventricular ejection fraction; NYHA -New York Heart Association; PADperipheral artery disease; TAPSEtricuspid annular plane systolic excursion; VADventricular assist device 
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